Philippe Rousselot

3.4k total citations
44 papers, 1.5k citations indexed

About

Philippe Rousselot is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Philippe Rousselot has authored 44 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 16 papers in Molecular Biology and 8 papers in Genetics. Recurrent topics in Philippe Rousselot's work include Acute Myeloid Leukemia Research (32 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Acute Lymphoblastic Leukemia research (8 papers). Philippe Rousselot is often cited by papers focused on Acute Myeloid Leukemia Research (32 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Acute Lymphoblastic Leukemia research (8 papers). Philippe Rousselot collaborates with scholars based in France, United States and Germany. Philippe Rousselot's co-authors include Xavier Thomas, Hervé Dombret, Carlos M. Galmarini, Fabien Calvo, Emeline Cros, Charles Dumontet, Jean‐Pierre Marolleau, J C Brouet, Emmanuel Raffoux and Jérôme Larghero and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Infectious Diseases.

In The Last Decade

Philippe Rousselot

40 papers receiving 1.5k citations

Peers

Philippe Rousselot
Odile Blanchet France
Jin Takeuchi Japan
C. Michel Zwaan Netherlands
Sylvain Thépot France
Eijiro Omoto Japan
Adriana Pleșa France
Anna Tamburini Italy
JL Harousseau France
Robert Schoch Germany
Nicholas Lea United Kingdom
Odile Blanchet France
Philippe Rousselot
Citations per year, relative to Philippe Rousselot Philippe Rousselot (= 1×) peers Odile Blanchet

Countries citing papers authored by Philippe Rousselot

Since Specialization
Citations

This map shows the geographic impact of Philippe Rousselot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Rousselot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Rousselot more than expected).

Fields of papers citing papers by Philippe Rousselot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Rousselot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Rousselot. The network helps show where Philippe Rousselot may publish in the future.

Co-authorship network of co-authors of Philippe Rousselot

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Rousselot. A scholar is included among the top collaborators of Philippe Rousselot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Rousselot. Philippe Rousselot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jabbour, Elias, Philippe Rousselot, Nicola Gökbuget, et al.. (2025). Inotuzumab Ozogamicin as First-Line Therapy in Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 25(5). e302–e309.
2.
Rosenquist, Richard, Elsa Bernard, Tom Erkers, et al.. (2023). Novel precision medicine approaches and treatment strategies in hematological malignancies. Journal of Internal Medicine. 294(4). 413–436. 22 indexed citations
3.
4.
Lambert, Juliette, Jérôme Lambert, Olivier Nibourel, et al.. (2014). MRD assessed byWT1andNPM1transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget. 5(15). 6280–6288. 59 indexed citations
5.
Kantarjian, Hagop M., Mikkael A. Sekeres, Vincent Ribrag, et al.. (2013). Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML. Clinical Lymphoma Myeloma & Leukemia. 13(5). 559–567. 46 indexed citations
6.
Pilorge, Sylvain, Sophie Rigaudeau, Florence Rabian, et al.. (2013). Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse. American Journal of Hematology. 89(4). 399–403. 19 indexed citations
7.
Preudhomme, Claude, Nathalie Hélevaut, Olivier Nibourel, et al.. (2011). Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leukemia Research. 36(3). 316–323. 44 indexed citations
8.
Rousselot, Philippe, et al.. (2011). False positive galactomannan Platelia due to piperacillin-tazobactam. Médecine et Maladies Infectieuses. 42(1). 10–14. 31 indexed citations
9.
Rousselot, Philippe. (2006). Que faire devant une carence martiale inexpliquée. Hématologie. 12(4). 220–220. 1 indexed citations
10.
Canioni, Danielle, Pauline Brice, Éric Lepage, et al.. (2004). Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d‘Etude des Lymphomes Folliculaires. British Journal of Haematology. 126(3). 364–371. 22 indexed citations
11.
Calvo, Fabien, Philippe Rousselot, Hervé Dombret, Jacques Médioni, & Samia Mourah. (2004). Vascular Endothelial Growth Factor 121 (VEGF121) Isoform mRNA Is Predictive of Poor Prognosis in Acute Myeloid Leukemia (AML) .. Blood. 104(11). 2007–2007. 1 indexed citations
12.
Galmarini, Carlos M., Xavier Thomas, Fabien Calvo, et al.. (2002). In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. British Journal of Haematology. 117(4). 860–868. 120 indexed citations
13.
Galmarini, Carlos M., Xavier Thomas, Fabien Calvo, et al.. (2002). Potential mechanisms of resistance to cytarabine in AML patients. Leukemia Research. 26(7). 621–629. 96 indexed citations
14.
Ionescu, Irina, Pauline Brice, D. Simon, et al.. (2000). Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients. Medical Oncology. 17(2). 127–134. 11 indexed citations
15.
Silva, Nicolas Da, Sandrine Meyer‐Monard, Antonio Parrado, et al.. (2000). Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO. The Hematology Journal. 1(5). 316–328. 15 indexed citations
16.
Maury, Sébastien, Thierry Leblanc, Philippe Rousselot, et al.. (1999). Bacteremia Due to Capnocytophaga Species in Patients with Neutropenia: High Frequency of β‐Lactamase‐Producing Strains. Clinical Infectious Diseases. 28(5). 1172–1174. 26 indexed citations
17.
18.
Rousselot, Philippe. (1996). Les conditions du langage politique : le point de vue de Cicéron. Bulletin de l Association Guillaume Budé. 1(3). 232–260.
19.
Aractingi, S., Claude Bachmeyer, O Vérola, et al.. (1995). Unusual specific cutaneous lesions in myelodysplastic syndromes. Journal of the American Academy of Dermatology. 33(2). 187–191. 31 indexed citations
20.
Duchayne, Éliane, Dominique Blanchard, Nelly Robillard, et al.. (1995). Minimally differentiated erythroleukaemia (AML M6 Variant'): a rare subset of AML distinct from AML M6. British Journal of Haematology. 90(4). 868–875. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Odile Blanchet Breakdown of academic impact, for papers by Jin Takeuchi Breakdown of academic impact, for papers by C. Michel Zwaan Breakdown of academic impact, for papers by Sylvain Thépot Breakdown of academic impact, for papers by Eijiro Omoto Breakdown of academic impact, for papers by Adriana Pleșa Breakdown of academic impact, for papers by Anna Tamburini Breakdown of academic impact, for papers by JL Harousseau Breakdown of academic impact, for papers by Robert Schoch Breakdown of academic impact, for papers by Nicholas Lea
Rankless by CCL
2026